{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:21:18Z","timestamp":1790716878278,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>This quantitative meta-analysis was conducted to evaluate the efficacy and safety of drug-eluting balloon (DEB) vs. uncoated balloon (UCB) in patients with femoropopliteal arterial occlusive disease.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Electronic databases were searched to identify randomized controlled trials (RCTs) that compared DEB and UCB till November 2018. The random-effects model was used for conducting pooled analyses.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Seventeen RCTs with 2706 patients were included in the final meta-analysis. Patients who received DEB had higher levels of minimal luminal diameter (MLD) at 6 (WMD: 0.77; 95%CI: 0.53 to 1.02; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and 12\u2009months (WMD: 1.33; 95%CI: 0.93 to 1.73; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) than those who received UCB. DEB reduced the late lumen loss (LLL) levels after 6 (WMD: -0.57; 95%CI: \u2212\u20091.07 to \u2212\u20090.06; <jats:italic>P<\/jats:italic>\u2009=\u20090.029) and 12\u2009months (WMD: -0.95; 95%CI: \u2212\u20091.28 to \u2212\u20090.62; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). DEB was found not superior over UCB on primary patency after 6\u2009months (RR: 1.44; 95%CI: 0.88\u20132.35; <jats:italic>P<\/jats:italic>\u2009=\u20090.149), whereas DEB increased the primary patency after 12 (RR: 1.51; 95%CI: 1.25\u20131.83; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and 24\u2009months (RR: 1.51; 95%CI: 1.30\u20131.77; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Patients who received DEB had reduced the risk of restenosis after 6 (RR: 0.47; 95%CI: 0.33\u20130.67; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and 12\u2009months (RR: 0.55; 95%CI: 0.35\u20130.85; <jats:italic>P<\/jats:italic>\u2009=\u20090.008). DEB reduced the risk of major adverse events after 6 (RR: 0.30; 95%CI: 0.14\u20130.61; <jats:italic>P<\/jats:italic>\u2009=\u20090.001), 12 (RR: 0.49; 95%CI: 0.32\u20130.76; <jats:italic>P<\/jats:italic>\u2009=\u20090.001) and 24\u2009months (RR: 0.62; 95%CI: 0.41\u20130.92; <jats:italic>P<\/jats:italic>\u2009=\u20090.018).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>DEB yielded additional benefits on MLD, LLL, primary patency, restenosis, TLR, and major adverse events than UCB in patients with femoropopliteal arterial occlusive disease.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12872-020-01667-y","type":"journal-article","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T10:03:10Z","timestamp":1598868190000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparison of efficacy and safety of drug-eluting versus uncoated balloon angioplasty for femoropopliteal arterial occlusive disease: a meta-analysis"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9508-0696","authenticated-orcid":false,"given":"Hai","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lishan","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,31]]},"reference":[{"key":"1667_CR1","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1161\/circulationaha.109.865600","volume":"120","author":"C Diehm","year":"2009","unstructured":"Diehm C, Allenberg JR, Pittrow D, Mahn M, Tepohl G, Haberl RL, et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation. 2009;120:2053\u201361. https:\/\/doi.org\/10.1161\/circulationaha.109.865600.","journal-title":"Circulation"},{"key":"1667_CR2","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/s0140-6736(13)61249-0","volume":"382","author":"FG Fowkes","year":"2013","unstructured":"Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382:1329\u201340. https:\/\/doi.org\/10.1016\/s0140-6736(13)61249-0.","journal-title":"Lancet"},{"key":"1667_CR3","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.jvs.2012.09.068","volume":"57","author":"MM McDermott","year":"2013","unstructured":"McDermott MM, Kibbe M, Guralnik JM, Pearce WH, Tian L, Liao Y, et al. Comparative effectiveness study of self-directed walking exercise, lower extremity revascularization, and functional decline in peripheral artery disease. J Vasc Surg. 2013;57:990\u20136.e1. https:\/\/doi.org\/10.1016\/j.jvs.2012.09.068.","journal-title":"J Vasc Surg"},{"key":"1667_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.pcad.2011.04.003","volume":"54","author":"M Schillinger","year":"2011","unstructured":"Schillinger M, Minar E. Claudication: treatment options for femoropopliteal disease. Prog Cardiovasc Dis. 2011;54:41\u20136. https:\/\/doi.org\/10.1016\/j.pcad.2011.04.003.","journal-title":"Prog Cardiovasc Dis"},{"key":"1667_CR5","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/eurheartj\/ehi098","volume":"26","author":"J Pache","year":"2005","unstructured":"Pache J, Dibra A, Mehilli J, Dirschinger J, Schomig A, Kastrati A. Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. Eur Heart J. 2005;26:1262\u20138. https:\/\/doi.org\/10.1093\/eurheartj\/ehi098.","journal-title":"Eur Heart J"},{"key":"1667_CR6","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.jvs.2016.05.084","volume":"64","author":"H Jongsma","year":"2016","unstructured":"Jongsma H, Bekken JA, de Vries JP, Verhagen HJ, Fioole B. Drug-eluting balloon angioplasty versus uncoated balloon angioplasty in patients with femoropopliteal arterial occlusive disease. J Vasc Surg. 2016;64:1503\u201314. https:\/\/doi.org\/10.1016\/j.jvs.2016.05.084.","journal-title":"J Vasc Surg"},{"key":"1667_CR7","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097.","journal-title":"PLoS Med"},{"key":"1667_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1\u201312.","journal-title":"Control Clin Trials"},{"key":"1667_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388.","journal-title":"Control Clin Trials"},{"key":"1667_CR10","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1177\/0272989x05282643","volume":"25","author":"AE Ades","year":"2005","unstructured":"Ades AE, Lu G, Higgins JP. The interpretation of random-effects meta-analysis in decision models. Med Decis Mak. 2005;25:646\u201354. https:\/\/doi.org\/10.1177\/0272989x05282643.","journal-title":"Med Decis Mak"},{"key":"1667_CR11","volume-title":"Cochrane handbook for systematic reviews of interventions 501. edn","author":"JJ Deeks","year":"2008","unstructured":"Deeks JJ, Higgins JPT, Altman DG. Analyzing data and undertaking meta-analyses. In: Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions 501. edn. Oxford: The Cochrane Collaboration; 2008."},{"key":"1667_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"key":"1667_CR13","first-page":"15","volume":"47","author":"A Tobias","year":"1999","unstructured":"Tobias A. Assessing the influence of a single study in meta-analysis. Stata Tech Bull. 1999;47:15\u20137.","journal-title":"Stata Tech Bull"},{"key":"1667_CR14","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/sim.1187","volume":"21","author":"SG Thompson","year":"2002","unstructured":"Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002;21:1559\u201373. https:\/\/doi.org\/10.1002\/sim.1187.","journal-title":"Stat Med"},{"key":"1667_CR15","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"1667_CR16","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088\u2013101.","journal-title":"Biometrics"},{"key":"1667_CR17","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/j.jcin.2016.06.055","volume":"9","author":"X Jia","year":"2016","unstructured":"Jia X, Zhang J, Zhuang B, Fu W, Wu D, Wang F, et al. Acotec drug-coated balloon catheter: randomized, multicenter, controlled clinical study in femoropopliteal arteries: evidence from the AcoArt I trial. JACC Cardiovasc Interv. 2016;9:1941\u20139. https:\/\/doi.org\/10.1016\/j.jcin.2016.06.055.","journal-title":"JACC Cardiovasc Interv"},{"key":"1667_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/1526602814564383","volume":"22","author":"D Scheinert","year":"2015","unstructured":"Scheinert D, Schulte KL, Zeller T, Lammer J, Tepe G. Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial. J Endovasc Ther. 2015;22:14\u201321. https:\/\/doi.org\/10.1177\/1526602814564383.","journal-title":"J Endovasc Ther"},{"key":"1667_CR19","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1016\/j.jcin.2015.07.011","volume":"8","author":"T Zeller","year":"2015","unstructured":"Zeller T, Beschorner U, Pilger E, Bosiers M, Deloose K, Peeters P, et al. Paclitaxel-coated balloon in infrapopliteal arteries: 12-month results from the BIOLUX P-II randomized trial (BIOTRONIK\u2019S-first in man study of the Passeo-18 LUX drug releasing PTA balloon catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal arteries). JACC Cardiovasc Interv. 2015;8:1614\u201322. https:\/\/doi.org\/10.1016\/j.jcin.2015.07.011.","journal-title":"JACC Cardiovasc Interv"},{"key":"1667_CR20","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1007\/s00270-018-1940-1","volume":"41","author":"T Albrecht","year":"2018","unstructured":"Albrecht T, Waliszewski M, Roca C, Redlich U, Tautenhahn J, Pech M, et al. Two-year clinical outcomes of the CONSEQUENT trial: can Femoropopliteal lesions be treated with sustainable clinical results that are economically sound? Cardiovasc Intervent Radiol. 2018;41:1008\u201314. https:\/\/doi.org\/10.1007\/s00270-018-1940-1.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"1667_CR21","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.jcin.2013.07.010","volume":"6","author":"F Liistro","year":"2013","unstructured":"Liistro F, Grotti S, Porto I, Angioli P, Ricci L, Ducci K, et al. Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery). JACC Cardiovasc Interv. 2013;6:1295\u2013302. https:\/\/doi.org\/10.1016\/j.jcin.2013.07.010.","journal-title":"JACC Cardiovasc Interv"},{"key":"1667_CR22","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1583\/jevt-12-3926mr.1","volume":"19","author":"F Fanelli","year":"2012","unstructured":"Fanelli F, Cannavale A, Boatta E, Corona M, Lucatelli P, Wlderk A, et al. Lower limb multilevel treatment with drug-eluting balloons: 6-month results from the DEBELLUM randomized trial. J Endovasc Ther. 2012;19:571\u201380. https:\/\/doi.org\/10.1583\/jevt-12-3926mr.1.","journal-title":"J Endovasc Ther"},{"key":"1667_CR23","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1161\/circulationaha.117.028893","volume":"136","author":"P Krishnan","year":"2017","unstructured":"Krishnan P, Faries P, Niazi K, Jain A, Sachar R, Bachinsky WB, et al. Stellarex drug-coated balloon for treatment of femoropopliteal disease: twelve-month outcomes from the randomized ILLUMENATE pivotal and pharmacokinetic studies. Circulation. 2017;136:1102\u201313. https:\/\/doi.org\/10.1161\/circulationaha.117.028893.","journal-title":"Circulation"},{"key":"1667_CR24","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1161\/circulationaha.116.026493","volume":"135","author":"H Schroeder","year":"2017","unstructured":"Schroeder H, Werner M, Meyer DR, Reimer P, Kruger K, Jaff MR, et al. Low-dose paclitaxel-coated versus uncoated percutaneous transluminal balloon angioplasty for femoropopliteal peripheral artery disease: one-year results of the ILLUMENATE European randomized clinical trial (randomized trial of a novel paclitaxel-coated percutaneous angioplasty balloon). Circulation. 2017;135:2227\u201336. https:\/\/doi.org\/10.1161\/circulationaha.116.026493.","journal-title":"Circulation"},{"key":"1667_CR25","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1161\/circulationaha.114.011004","volume":"131","author":"G Tepe","year":"2015","unstructured":"Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131:495\u2013502. https:\/\/doi.org\/10.1161\/circulationaha.114.011004.","journal-title":"Circulation"},{"key":"1667_CR26","doi-asserted-by":"publisher","first-page":"528","DOI":"10.23736\/s0021-9509.16.09685-3","volume":"58","author":"E Debing","year":"2017","unstructured":"Debing E, Aerden D, Vanhulle A, Gallala S, von Kemp K. Paclitaxel-coated versus plain old balloon angioplasty for the treatment of infrainguinal arterial disease in diabetic patients: the Belgian diabetic IN.PACT Trial. J Cardiovasc Surg (Torino). 2017;58:528\u201334. https:\/\/doi.org\/10.23736\/s0021-9509.16.09685-3.","journal-title":"J Cardiovasc Surg (Torino)"},{"key":"1667_CR27","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1161\/circulationaha.116.025329","volume":"135","author":"I Ott","year":"2017","unstructured":"Ott I, Cassese S, Groha P, Steppich B, Hadamitzky M, Ibrahim T, et al. Randomized comparison of paclitaxel-eluting balloon and stenting versus plain balloon plus stenting versus directional atherectomy for femoral artery disease (ISAR-STATH). Circulation. 2017;135:2218\u201326. https:\/\/doi.org\/10.1161\/circulationaha.116.025329.","journal-title":"Circulation"},{"key":"1667_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jcin.2013.05.022","volume":"7","author":"D Scheinert","year":"2014","unstructured":"Scheinert D, Duda S, Zeller T, Krankenberg H, Ricke J, Bosiers M, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014;7:10\u20139. https:\/\/doi.org\/10.1016\/j.jcin.2013.05.022.","journal-title":"JACC Cardiovasc Interv"},{"key":"1667_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa1406235","volume":"373","author":"K Rosenfield","year":"2015","unstructured":"Rosenfield K, Jaff MR, White CJ, Rocha-Singh K, Mena-Hurtado C, Metzger DC, et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373:145\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1406235.","journal-title":"N Engl J Med"},{"key":"1667_CR30","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1161\/circinterventions.112.971630","volume":"5","author":"M Werk","year":"2012","unstructured":"Werk M, Albrecht T, Meyer DR, Ahmed MN, Behne A, Dietz U, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5:831\u201340. https:\/\/doi.org\/10.1161\/circinterventions.112.971630.","journal-title":"Circ Cardiovasc Interv"},{"key":"1667_CR31","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.jcin.2016.04.012","volume":"9","author":"CM Kinstner","year":"2016","unstructured":"Kinstner CM, Lammer J, Willfort-Ehringer A, Matzek W, Gschwandtner M, Javor D, et al. Paclitaxel-eluting balloon versus standard balloon angioplasty in in-stent restenosis of the superficial femoral and proximal popliteal artery: 1-year results of the PACUBA trial. JACC Cardiovasc Interv. 2016;9:1386\u201392. https:\/\/doi.org\/10.1016\/j.jcin.2016.04.012.","journal-title":"JACC Cardiovasc Interv"},{"key":"1667_CR32","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1056\/NEJMoa0706356","volume":"358","author":"G Tepe","year":"2008","unstructured":"Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwalder U, Beregi JP, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689\u201399. https:\/\/doi.org\/10.1056\/NEJMoa0706356.","journal-title":"N Engl J Med"},{"key":"1667_CR33","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1161\/circulationaha.107.735985","volume":"118","author":"M Werk","year":"2008","unstructured":"Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, Dietz U, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118:1358\u201365. https:\/\/doi.org\/10.1161\/circulationaha.107.735985.","journal-title":"Circulation"},{"key":"1667_CR34","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1161\/circinterventions.112.969972","volume":"5","author":"S Cassese","year":"2012","unstructured":"Cassese S, Byrne RA, Ott I, Ndrepepa G, Nerad M, Kastrati A, et al. Paclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: a meta-analysis of randomized trials. Circ Cardiovasc Interv. 2012;5:582\u20139. https:\/\/doi.org\/10.1161\/circinterventions.112.969972.","journal-title":"Circ Cardiovasc Interv"},{"key":"1667_CR35","doi-asserted-by":"publisher","unstructured":"Kayssi A, Al-Atassi T, Oreopoulos G, Roche-Nagle G, Tan KT, Rajan DK. Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs. Cochrane Database Syst Rev. 2016:Cd011319. https:\/\/doi.org\/10.1002\/14651858.CD011319.pub2.","DOI":"10.1002\/14651858.CD011319.pub2"},{"key":"1667_CR36","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.jcin.2016.06.008","volume":"9","author":"D Giacoppo","year":"2016","unstructured":"Giacoppo D, Cassese S, Harada Y, Colleran R, Michel J, Fusaro M, et al. Drug-coated balloon versus plain balloon angioplasty for the treatment of femoropopliteal artery disease: an updated systematic review and meta-analysis of randomized clinical trials. JACC Cardiovasc Interv. 2016;9:1731\u201342. https:\/\/doi.org\/10.1016\/j.jcin.2016.06.008.","journal-title":"JACC Cardiovasc Interv"},{"key":"1667_CR37","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.jvir.2017.08.003","volume":"28","author":"MR Jaff","year":"2017","unstructured":"Jaff MR, Nelson T, Ferko N, Martinson M, Anderson LH, Hollmann S. Endovascular Interventions for femoropopliteal peripheral artery disease: a network meta-analysis of current technologies. J Vasc Interv Radiol. 2017;28:1617\u201327.e1. https:\/\/doi.org\/10.1016\/j.jvir.2017.08.003.","journal-title":"J Vasc Interv Radiol"},{"key":"1667_CR38","doi-asserted-by":"publisher","first-page":"e011245","DOI":"10.1161\/JAHA.118.011245","volume":"7","author":"K Katsanos","year":"2018","unstructured":"Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7:e011245. https:\/\/doi.org\/10.1161\/JAHA.118.011245.","journal-title":"J Am Heart Assoc"},{"key":"1667_CR39","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.eclinm.2019.09.004","volume":"16","author":"C Klumb","year":"2019","unstructured":"Klumb C, Lehmann T, Aschenbach R, Eckardt N, Teichgr\u00e4ber U. Benefit and risk from paclitaxel-coated balloon angioplasty for the treatment of femoropopliteal artery disease: a systematic review and meta-analysis of randomised controlled trials. EClinicalMedicine. 2019;16:42\u201350. https:\/\/doi.org\/10.1016\/j.eclinm.2019.09.004.","journal-title":"EClinicalMedicine"},{"key":"1667_CR40","doi-asserted-by":"publisher","first-page":"e0186220","DOI":"10.1371\/journal.pone.0186220","volume":"12","author":"V Cornejo Del Rio","year":"2017","unstructured":"Cornejo Del Rio V, Mostaza J, Lahoz C, Sanchez-Arroyo V, Sabin C, Lopez S, et al. Prevalence of peripheral artery disease (PAD) and factors associated: an epidemiological analysis from the population-based screening PRE-diabetes and type 2 DIAbetes (SPREDIA-2) study. PLoS One. 2017;12:e0186220. https:\/\/doi.org\/10.1371\/journal.pone.0186220.","journal-title":"PLoS One"},{"key":"1667_CR41","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/nrcardio.2016.179","volume":"14","author":"FG Fowkes","year":"2017","unstructured":"Fowkes FG, Aboyans V, Fowkes FJ, McDermott MM, Sampson UK, Criqui MH. Peripheral artery disease: epidemiology and global perspectives. Nat Rev Cardiol. 2017;14:156\u201370. https:\/\/doi.org\/10.1038\/nrcardio.2016.179.","journal-title":"Nat Rev Cardiol"},{"key":"1667_CR42","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.redox.2017.04.017","volume":"12","author":"S Steven","year":"2017","unstructured":"Steven S, Daiber A, Dopheide JF, Munzel T, Espinola-Klein C. Peripheral artery disease, redox signaling, oxidative stress - basic and clinical aspects. Redox Biol. 2017;12:787\u201397. https:\/\/doi.org\/10.1016\/j.redox.2017.04.017.","journal-title":"Redox Biol"},{"issue":"23","key":"1667_CR43","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1161\/CIRCULATIONAHA.119.044697","volume":"141","author":"KJ Rocha-Singh","year":"2020","unstructured":"Rocha-Singh KJ, Duval S, Jaff MR, et al. Mortality and paclitaxel-coated devices: an individual patient data meta-analysis. Circulation. 2020;141(23):1859\u201369. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044697.","journal-title":"Circulation"},{"key":"1667_CR44","doi-asserted-by":"publisher","unstructured":"Freisinger E, Koeppe J, Gerss J, et al. Mortality after use of paclitaxel-based devices in peripheral arteries: a real-world safety analysis. Eur Heart J. 2019:ehz698. https:\/\/doi.org\/10.1093\/eurheartj\/ehz698 [published online ahead of print, 2019 Oct 8].","DOI":"10.1093\/eurheartj\/ehz698"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-020-01667-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-020-01667-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-020-01667-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T23:25:06Z","timestamp":1630365906000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-020-01667-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,31]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1667"],"URL":"https:\/\/doi.org\/10.1186\/s12872-020-01667-y","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,31]]},"assertion":[{"value":"22 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no any conflict of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"395"}}